Wound healing is a precisely orchestrated biological process involving cellular migration, cytokine signaling, matrix remodeling, and angiogenesis — a cascade that, when disrupted, results in the chronic wounds that affect 6.5 million Americans and cost the healthcare system $25 billion annually. Understanding normal wound healing biology and the specific molecular disruptions that characterize chronic wounds is essential for evidence-based advanced wound product selection. Our wound care catalog carries over 35,000 products from Mölnlycke, Smith+Nephew, ConvaTec, and Coloplast — covering the full spectrum from acute wound care to biofilm management to advanced biologics.
Normal Wound Healing: The Four Phases
Hemostasis (0–1 hours): platelet aggregation and fibrin clot formation; platelet α-granules release PDGF, TGF-β, and EGF providing the initial growth factor signal to recruit inflammatory cells. Inflammation (1–4 days): neutrophil and macrophage infiltration — neutrophils debride bacteria and necrotic tissue; macrophages transition from pro-inflammatory (M1, days 1–3) to pro-healing (M2, days 3+), releasing VEGF for angiogenesis, TGF-β for fibroblast recruitment, and IGF-1 for epithelial migration. Proliferation (4–21 days): fibroblast proliferation and matrix deposition, angiogenesis, keratinocyte migration across the wound surface. Remodeling (21 days–2 years): type III collagen (provisional matrix) replaced by type I collagen; matrix metalloproteinases (MMPs) remodel the scar. Wound strength reaches 50% of original at 6 weeks and maximum 80% at 2 years — hence surgical wound dehiscence risk during the proliferative phase.
What Goes Wrong in Chronic Wounds
Chronic wounds are "stuck" in the inflammatory phase — unable to progress through the proliferative transition. Molecular characteristics of chronic wound fluid vs acute wound fluid: elevated MMP-2, MMP-9, MMP-8 that degrade growth factors (VEGF, PDGF, EGF) before they can bind receptors; elevated pro-inflammatory cytokines (TNF-α, IL-1β); senescent fibroblasts unable to proliferate normally; and — critically — bacterial biofilm (present in >78% of chronic wounds, contributing to the sustained inflammatory state). This molecular environment explains why simply dressing a chronic wound without addressing biofilm and the MMP-dominated wound bed is ineffective — advanced wound products that either inhibit MMPs (PROMOGRAN containing oxidized regenerated cellulose) or address biofilm (antimicrobial dressings, NPWT, sharp debridement) are required to shift the wound toward the healing trajectory. Our advanced wound care section includes the complete range of biofilm-targeting and growth factor-supporting wound products.
